Ascidian Advances RNA Editing Therapy ACDN-01 into Pediatric Trial for Stargardt Disease

Ascidian Advances RNA Editing Therapy ACDN-01 into Pediatric Trial for Stargardt Disease

By, Admin 6 May 2026

In genetic medicine, most approaches try to replace or edit DNA. Ascidian Therapeutics is taking a different route—rewriting RNA. That strategy is now moving forward clinically.

The company has completed the adult dose-escalation phase of its STELLAR trial for ACDN-01 and is expanding the study to include pediatric patients aged 12 and older—a critical step for a disease that often begins early in life.

Why This Matters: Targeting the Root Cause

Stargardt disease is not just rare—it’s genetically complex.

  • Caused by mutations in the ABCA4 gene
  • Over 1,000 known variants
  • Leads to progressive retinal degeneration and vision loss
  • Typically begins in childhood or adolescence

And here’s the problem:
→ Traditional gene therapies struggle here.

Why?

  • The ABCA4 gene is too large for standard gene replacement
  • Mutation diversity makes single-edit solutions impractical

That’s where ACDN-01 stands out.

The Science: RNA Editing Instead of DNA Editing

ACDN-01 is built on a first-in-class approach:

  • Performs in vivo RNA exon editing
  • Restores full-length ABCA4 protein
  • Uses a single AAV vector
  • Does not modify DNA
  • Does not introduce foreign enzymes

In simple terms:
→ It fixes the message (RNA), not the blueprint (DNA)

Potential advantages:

  • Avoids permanent genome changes
  • Works across multiple mutation types
  • Enables precise, controlled protein restoration

Inside the STELLAR Trial

The STELLAR study is a Phase 1/2, multi-center, open-label trial evaluating safety and early efficacy. Key details:

  • Delivery: Single subretinal injection
  • Participants (so far):
    • 10 adults (ages 18–77) in dose-escalation phase
  • Next phase:
    • Pediatric expansion (ages 12+) now underway

The move into younger patients is significant: Earlier intervention could preserve more vision.

First Human Data Incoming

Initial safety data from STELLAR will be presented at the American Society of Gene & Cell Therapy Annual Meeting on May 12. This will be the first clinical readout for ACDN-01 in humans. For a first-in-class modality, that’s a major inflection point.

Supporting Study: STARPATH

Alongside STELLAR, Ascidian has launched STARPATH, an observational study.

Purpose:

  • Enroll patients aged 5+
  • Conduct genetic testing
  • Perform high-resolution retinal imaging

Why it matters:

  • Builds a well-characterized patient pool
  • Supports future trial recruitment
  • Helps refine endpoints and disease understanding

The Bigger Constraint in Stargardt Therapy

Stargardt disease has long resisted drug development. Key challenges:

  • Large gene size (ABCA4)
  • High mutation variability
  • Lack of approved therapies

Current status: No FDA-approved treatments exist This makes ACDN-01’s approach particularly compelling—if it works.

Preclinical Signals: Promising but Early

Before entering the clinic, ACDN-01 showed:

  • Durable RNA editing
  • Efficient restoration of ABCA4 protein
  • Success in:
    • Non-human primates
    • Human retinal explant models

But let’s be clear: Preclinical success doesn’t guarantee clinical outcomes. The upcoming human data will determine whether this platform translates.

Strategic Positioning: First-in-Class RNA Exon Editing

ACDN-01 is currently:

  • The only clinical-stage therapy using this specific RNA exon editing approach for Stargardt
  • A potential platform technology for other large-gene disorders

If validated, this could open doors beyond ophthalmology.

Bottom Line

Ascidian isn’t just advancing a drug—it’s testing a new category of genetic medicine.

  • Adult dose escalation complete
  • Pediatric expansion underway
  • First human data imminent

The upside is massive:  A disease-modifying therapy for a condition with zero approved options

The risk is equally real: First-in-class biology, unproven in humans

For now, the story hinges on one thing: Does RNA editing deliver where DNA-based approaches couldn’t?

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!